201 related articles for article (PubMed ID: 19441917)
1. Checkpoint kinase inhibitors: a review of the patent literature.
Janetka JW; Ashwell S
Expert Opin Ther Pat; 2009 Feb; 19(2):165-97. PubMed ID: 19441917
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint kinase inhibitors: a patent review (2009 - 2010).
Lainchbury M; Collins I
Expert Opin Ther Pat; 2011 Aug; 21(8):1191-210. PubMed ID: 21599421
[TBL] [Abstract][Full Text] [Related]
3. Drug discovery targeting Chk1 and Chk2 kinases.
Zhou BB; Sausville EA
Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of checkpoint kinases: from discovery to the clinic.
Janetka JW; Ashwell S; Zabludoff S; Lyne P
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):473-86. PubMed ID: 17659489
[TBL] [Abstract][Full Text] [Related]
5. Anticancer therapy with checkpoint inhibitors: what, where and when?
Garrett MD; Collins I
Trends Pharmacol Sci; 2011 May; 32(5):308-16. PubMed ID: 21458083
[TBL] [Abstract][Full Text] [Related]
6. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
[TBL] [Abstract][Full Text] [Related]
7. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors.
Saleem RS; Lansdell TA; Tepe JJ
Bioorg Med Chem; 2012 Feb; 20(4):1475-81. PubMed ID: 22285028
[TBL] [Abstract][Full Text] [Related]
9. Current inhibitors of checkpoint kinase 2.
Nguyen TN; Tepe JJ
Curr Med Chem; 2011; 18(28):4368-74. PubMed ID: 21861812
[TBL] [Abstract][Full Text] [Related]
10. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage.
Bahassi EM; Ovesen JL; Riesenberg AL; Bernstein WZ; Hasty PE; Stambrook PJ
Oncogene; 2008 Jun; 27(28):3977-85. PubMed ID: 18317453
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.
Janetka JW; Almeida L; Ashwell S; Brassil PJ; Daly K; Deng C; Gero T; Glynn RE; Horn CL; Ioannidis S; Lyne P; Newcombe NJ; Oza VB; Pass M; Springer SK; Su M; Toader D; Vasbinder MM; Yu D; Yu Y; Zabludoff SD
Bioorg Med Chem Lett; 2008 Jul; 18(14):4242-8. PubMed ID: 18547806
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.
Matthews TP; Jones AM; Collins I
Expert Opin Drug Discov; 2013 Jun; 8(6):621-40. PubMed ID: 23594139
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.
Oza V; Ashwell S; Brassil P; Breed J; Deng C; Ezhuthachan J; Haye H; Horn C; Janetka J; Lyne P; Newcombe N; Otterbien L; Pass M; Read J; Roswell S; Su M; Toader D; Yu D; Yu Y; Valentine A; Webborn P; White A; Zabludoff S; Zheng X
Bioorg Med Chem Lett; 2010 Sep; 20(17):5133-8. PubMed ID: 20673630
[TBL] [Abstract][Full Text] [Related]
14. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer.
Li Q; Zhu GD
Curr Top Med Chem; 2002 Sep; 2(9):939-71. PubMed ID: 12171565
[TBL] [Abstract][Full Text] [Related]
15. DNA-damage response in the basidiomycete fungus Ustilago maydis relies in a sole Chk1-like kinase.
Pérez-Martín J
DNA Repair (Amst); 2009 Jun; 8(6):720-31. PubMed ID: 19269260
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine.
Curman D; Cinel B; Williams DE; Rundle N; Block WD; Goodarzi AA; Hutchins JR; Clarke PR; Zhou BB; Lees-Miller SP; Andersen RJ; Roberge M
J Biol Chem; 2001 May; 276(21):17914-9. PubMed ID: 11279124
[TBL] [Abstract][Full Text] [Related]
17. Chk1 inhibitors for novel cancer treatment.
Tao ZF; Lin NH
Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel substrates for human checkpoint kinase Chk1 and Chk2 through genome-wide screening using a consensus Chk phosphorylation motif.
Kim MA; Kim HJ; Brown AL; Lee MY; Bae YS; Park JI; Kwak JY; Chung JH; Yun J
Exp Mol Med; 2007 Apr; 39(2):205-12. PubMed ID: 17464182
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CHK1 kinase by Gö6976 converts 8-chloro-adenosine-induced G2/M arrest into S arrest in human myelocytic leukemia K562 cells.
Jia XZ; Yang SY; Zhou J; Li SY; Ni JH; An GS; Jia HT
Biochem Pharmacol; 2009 Mar; 77(5):770-80. PubMed ID: 19059218
[TBL] [Abstract][Full Text] [Related]
20. The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint.
Ho CC; Siu WY; Chow JP; Lau A; Arooz T; Tong HY; Ng IO; Poon RY
Exp Cell Res; 2005 Mar; 304(1):1-15. PubMed ID: 15707569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
